Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 11, 2001, Pages 3162-3170

  Cruz, M C ^a   Goldstein, A L ^a   Blankenship, J ^a   Del Poeta, M ^a   Perfect, J R ^a   McCusker, J H ^a   Bennani, Y L ^a   Cardenas, M E ^a   Heitman, J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE; IMMUNOSUPPRESSIVE AGENT; PHOSPHOTRANSFERASE; PYRROLE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; DRUG MECHANISM; ENZYME INHIBITION; GENE DISRUPTION; GENOTYPE; GROWTH INHIBITION; IMMUNOSUPPRESSIVE TREATMENT; MUTATION; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIA; DNA PRIMERS; DRUG RESISTANCE; FUNGAL PROTEINS; IMMUNOSUPPRESSIVE AGENTS; MUTAGENESIS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SIROLIMUS; TACROLIMUS BINDING PROTEIN 1A;

EID: 0034774478     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.11.3162-3170.2001     Document Type: Article

References (70)

1. Dissection of autophagosome biogenesis into distinct nucleation and expansion steps
2. Mammalian RAFT1 kinase domain provides rapamycin-sensitive. TOR function in yeast
3. Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast
4. Rapamycin (AY-22,989), a new antifungal antibiotic. III. in vitro and in vivo evaluation
5. 1 progression in yeast
6. The TOR signalling pathway controls nuclear localization of nutrient-regulated transcription factors
7. The TOR (target of rapamycin) signal transduction pathway regulates the stability of translation initiation factor eIF4G in the yeast Saccharomyces cerevisiae
8. Tripartite regulation of Gln3p by TOR, Ure2p and phosphatases
9. 5-Fluoroorotic acid as a selective agent in yeast molecular genetics
10. 1-arresting rapamycin-receptor complex
11. Control of p70 S6 kinase by kinase activity of FRAP in vivo
12. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity
13. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action
14. The TOR signaling cascade regulates gene expression in response to nutrients
15. FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity
16. Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands
17. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP
18. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans
19. Immunosuppressive and nonimmunosuppressive cyctosporin analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin dependent inhibition of calcineurin
20. Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans
21. Structure: In vitro activity relationships of pentamidine analogues and dication-substituted bis-benzimidazoles as new antifungal agents
22. Antifungal rapamycin analogues with reduced immunosuppressive activity
23. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-D-glucan synthase inhibitors
24. Enhancement of the antifungal activity of rapamycin by the coproduced elaiophylin and nigericin
25. Cloning and sequence analysis of a rapamycin-binding protein-encoding gene (RBP1) from Candida albicans
26. The two-hybrid system to detect protein-protein interactions
27. Isogenic strain construction and gene mapping in Candida albicans
28. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
29. Antifungal agents: Chemotherapeutic targets and immunologic strategies
30. Heterologous URA3MX cassettes for gene replacement in Saccharomyces cerevisiae
31. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins
32. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyctin-dependent kinases
33. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast
34. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast
35. The antimicrobial activities of cyclosporine, FK506, and rapamycin
36. Invasive aspergillosis in mice immunosuppressed with cyclosporin A, tacrolimus (FK506), or sirolimus (rapamycin)
37. Sirolimus: Continuing the evolution of transplant immunosuppression
38. Tor-mediated induction of autophagy via an Apg1 protein kinase complex
39. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression
40. Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary Aspergillosis
41. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin
42. Structure-activity studies of rapamycin analogs: Evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface
43. The α-mating type locus of Cryptococcus neoformans contains a peptide pheromone gene
44. Green fluorescent protein as a marker for gene expression and subcellular localization in budding yeast
45. TOR, a phosphatidylinositol kinase homologue, controls autophagy in yeast
46. Calcineurin is required for virulence of Cryptococcus neoformans
47. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein
48. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin
49. Role of newer azoles in surgical patients
50. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits
51. Anti-fungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
52. Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae
53. The Tor kinases link nutrient sensing to cell growth
54. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs
55. Rapamycin in transplantation: A review of the evidence
56. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae
57. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue
58. An improved protocol for the preparation of yeast cells for transformation by electroporation
59. Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA
60. Treatment of Cryptococcal meningitis associated with the acquired immunodeficiency syndrome
61. Rapamycin (AY-22,989), a new antifungal antibiotic. 1. Taxonomy of the producing Streptomycete and isolation of the active principle
62. +, is required for the response to starvation and other stresses via a conserved serine
63. Rapamycin specifically interferes with the developmental response of fission yeast to starvation
64. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
65. Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions
66. Antifungal activities of rapamycin and its derivatives, prolylrapamycin, 32-desmethylrapamycin, and 32-desmethoxyrapamycin
67. o program of transcriptional repression in yeast by interfering with the TOR signaling pathway
68. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin